569 related articles for article (PubMed ID: 9816264)
1. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
3. Maintenance and expansion of erythropoiesis in human long-term bone marrow cultures in presence of erythropoietin plus stem cell factor and interleukin-3 or interleukin-11.
Hassan HT; Biermann B; Zander AR
Eur Cytokine Netw; 1996; 7(2):129-36. PubMed ID: 8688490
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
5. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
Aoki A; Shibata A
Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of autocrine transforming growth factor-beta in human cord blood CD34(+)CD38(-)Lin(-) cells promotes stem-cell-factor-mediated erythropoietin-independent early erythroid progenitor development and reduces terminal differentiation.
Akel S; Petrow-Sadowski C; Laughlin MJ; Ruscetti FW
Stem Cells; 2003; 21(5):557-67. PubMed ID: 12968110
[TBL] [Abstract][Full Text] [Related]
7. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
8. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
12. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha.
Tsopra OA; Ziros PG; Lagadinou ED; Symeonidis A; Kouraklis-Symeonidis A; Thanopoulou E; Angelopoulou MK; Vassilakopoulos TP; Pangalis GA; Zoumbos NC
Acta Haematol; 2009; 121(4):187-95. PubMed ID: 19468203
[TBL] [Abstract][Full Text] [Related]
13. The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.
Verbeek W; Vehmeyer K; Wörmann B; Hiddemann W
J Cancer Res Clin Oncol; 1995; 121(6):338-42. PubMed ID: 7797598
[TBL] [Abstract][Full Text] [Related]
14. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
[TBL] [Abstract][Full Text] [Related]
15. In vitro proliferation and differentiation of erythroid progenitors of cord blood.
Sakatoku H; Inoue S
Stem Cells; 1997; 15(4):268-74. PubMed ID: 9253110
[TBL] [Abstract][Full Text] [Related]
16. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin.
Muta K; Krantz SB
J Cell Physiol; 1993 Aug; 156(2):264-71. PubMed ID: 7688370
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
19. Expression and function of c-kit receptor in bone marrow mononuclear cells of patients with myelodysplastic syndromes.
Shao Z; Zhang H; Chen G; Wang L; Li K; Zhang Y; Li L; Sun J
Chin Med J (Engl); 2001 May; 114(5):481-5. PubMed ID: 11780408
[TBL] [Abstract][Full Text] [Related]
20. A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis.
Liu B; Ohishi K; Yamamura K; Suzuki K; Monma F; Ino K; Nishii K; Masuya M; Sekine T; Heike Y; Takaue Y; Katayama N
Exp Hematol; 2010 Aug; 38(8):685-95. PubMed ID: 20381581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
